Therapy Areas: Inflammatory Diseases
Lynk Pharmaceuticals reports first patient dosed in Phase II clinical trial for vitiligo treatment
9 July 2026 - Lynk Pharmaceuticals Co Ltd, a clinical-stage innovative drug development company focused on immune and inflammatory diseases, announced on Wednesday that the first patient has been succ...
AbbVie receives positive CHMP opinion for upadacitinib in severe alopecia areata
29 June 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) said on Monday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human U...
Evommune reports Phase 2b trial miss for EVO756 in chronic spontaneous urticaria
29 June 2026 - Biotechnology company Evommune Inc (NYSE: EVMN) disclosed on Monday that its Phase 2b trial evaluating EVO756 in moderate-to-severe chronic spontaneous urticaria did not meet its primar...
AbbVie receives positive CHMP opinion for upadacitinib in non‑segmental vitiligo
29 June 2026 - US biopharmaceutical company AbbVie (NYSE: ABBV) announced on Monday it has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Hu...
NeuroSense reports Phase 2 proof-of-concept study results for PrimeC in Alzheimer's Disease
26 June 2026 - Late-clinical stage biotechnology company NeuroSense Therapeutics Ltd (NASDAQ:NRSN) on Thursday reported positive biomarker findings from its Phase 2 randomised, double-blind, placebo-c...
Vascarta announces VAS-101 Phase I results in sickle cell disease patients
25 June 2026 - Clinical-stage biopharmaceutical company Vascarta Inc announced on Wednesday the successful completion of the sublingual arm of its Phase I clinical trial evaluating VAS-101 (Vasceptor;...